Next, we therefore tested whether ACAT inhibition could enhance the capacity of HBV-specific TCR-gene-modified CD8+ T cells to recognise and kill a hepatoma line (HepG2) presenting cognate peptide. This evidence concerns the gene ACAT1 and hepatocellular carcinoma.